CTLA4 and neoplasm: In addition to the established, albeit toxic and rather ineffective treatments of interferon alpha in the adjuvant setting and Interleukin 2 in the advanced setting, new therapies with anti-CTLA-4 antibodies or specific (individualized) tumor vaccines are being developed.